Studies have also found that the secretion of growth factor TGFβ1 by CAFs contributes to increased resistance to photodynamic therapy, signifying that CAF-secreted TGFβ1 can be used as a biomarker to determine the effectiveness of photodynamic therapy in cSCC patients [144]. This evidence concerns the gene TGFB1 and skin squamous cell carcinoma.